Accelerated erythroid repopulation with no stem-cell competition effect in children treated with recombinant human erythropoietin after allogeneic bone marrow transplantation

F. Locatelli, M. Zecca, Y. Beguin, G. Giorgiani, L. Ponchio, P. De Stefano, M. Cazzola

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We carried out a pilot study on the use of recombinant human erythropoietin (rHuEPO) to accelerate erythropoietic engraftment in paediatric patients undergoing allogeneic BMT. rHuEPO was administered intravenously at a dose of 75 U/kg per day for 30 d after transplant. Erythroid repopulation, evaluated sequentially through the serum transferrin receptor, was faster in 15 patients receiving rHuEPO than in 16 historical controls (P = 0.0003). This faster erythroid engraftment resulted in a reduction in the total number of red blood cell units required to reach transfusion independence (2.7 ± 1.2 v 4.2 ± 2.3, P = 0.027). No significant difference in leucocyte or platelet regeneration was observed. These findings indicate that rHuEPO administration can accelerate erythroid recovery after allogeneic BMT and reduce red cell transfusion requirements with no stem-cell competition effect.

Original languageEnglish
Pages (from-to)752-754
Number of pages3
JournalBritish Journal of Haematology
Volume84
Issue number4
Publication statusPublished - 1993

Fingerprint

Homologous Transplantation
Erythropoietin
Bone Marrow Transplantation
Stem Cells
Transferrin Receptors
Regeneration
Leukocytes
Blood Platelets
Erythrocytes
Pediatrics
Transplants
Serum

ASJC Scopus subject areas

  • Hematology

Cite this

@article{9b2eb91c899648f2a372516a9f787be7,
title = "Accelerated erythroid repopulation with no stem-cell competition effect in children treated with recombinant human erythropoietin after allogeneic bone marrow transplantation",
abstract = "We carried out a pilot study on the use of recombinant human erythropoietin (rHuEPO) to accelerate erythropoietic engraftment in paediatric patients undergoing allogeneic BMT. rHuEPO was administered intravenously at a dose of 75 U/kg per day for 30 d after transplant. Erythroid repopulation, evaluated sequentially through the serum transferrin receptor, was faster in 15 patients receiving rHuEPO than in 16 historical controls (P = 0.0003). This faster erythroid engraftment resulted in a reduction in the total number of red blood cell units required to reach transfusion independence (2.7 ± 1.2 v 4.2 ± 2.3, P = 0.027). No significant difference in leucocyte or platelet regeneration was observed. These findings indicate that rHuEPO administration can accelerate erythroid recovery after allogeneic BMT and reduce red cell transfusion requirements with no stem-cell competition effect.",
author = "F. Locatelli and M. Zecca and Y. Beguin and G. Giorgiani and L. Ponchio and {De Stefano}, P. and M. Cazzola",
year = "1993",
language = "English",
volume = "84",
pages = "752--754",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "4",

}

TY - JOUR

T1 - Accelerated erythroid repopulation with no stem-cell competition effect in children treated with recombinant human erythropoietin after allogeneic bone marrow transplantation

AU - Locatelli, F.

AU - Zecca, M.

AU - Beguin, Y.

AU - Giorgiani, G.

AU - Ponchio, L.

AU - De Stefano, P.

AU - Cazzola, M.

PY - 1993

Y1 - 1993

N2 - We carried out a pilot study on the use of recombinant human erythropoietin (rHuEPO) to accelerate erythropoietic engraftment in paediatric patients undergoing allogeneic BMT. rHuEPO was administered intravenously at a dose of 75 U/kg per day for 30 d after transplant. Erythroid repopulation, evaluated sequentially through the serum transferrin receptor, was faster in 15 patients receiving rHuEPO than in 16 historical controls (P = 0.0003). This faster erythroid engraftment resulted in a reduction in the total number of red blood cell units required to reach transfusion independence (2.7 ± 1.2 v 4.2 ± 2.3, P = 0.027). No significant difference in leucocyte or platelet regeneration was observed. These findings indicate that rHuEPO administration can accelerate erythroid recovery after allogeneic BMT and reduce red cell transfusion requirements with no stem-cell competition effect.

AB - We carried out a pilot study on the use of recombinant human erythropoietin (rHuEPO) to accelerate erythropoietic engraftment in paediatric patients undergoing allogeneic BMT. rHuEPO was administered intravenously at a dose of 75 U/kg per day for 30 d after transplant. Erythroid repopulation, evaluated sequentially through the serum transferrin receptor, was faster in 15 patients receiving rHuEPO than in 16 historical controls (P = 0.0003). This faster erythroid engraftment resulted in a reduction in the total number of red blood cell units required to reach transfusion independence (2.7 ± 1.2 v 4.2 ± 2.3, P = 0.027). No significant difference in leucocyte or platelet regeneration was observed. These findings indicate that rHuEPO administration can accelerate erythroid recovery after allogeneic BMT and reduce red cell transfusion requirements with no stem-cell competition effect.

UR - http://www.scopus.com/inward/record.url?scp=0027182268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027182268&partnerID=8YFLogxK

M3 - Article

VL - 84

SP - 752

EP - 754

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -